BIOMAT Database Logo BIOMAT Database Logo

[Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy]. 2004

P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Unidad de Inmunodeficiencias, Departamento de Pediatría, Hospital 12 de Octubre, Madrid, España. pablorojoconejo@netscape.net

BACKGROUND In developed countries, the introduction of highly active antiretroviral therapy (HAART) has greatly improved survival and quality of life in HIV-infected children. Nevertheless, worrisome metabolic and bone alterations are beginning to be observed. OBJECTIVE To evaluate the prevalence of alterations in bone mineral density and possible associated factors in a cohort of HIV-infected children receiving HAART. METHODS Bone dual energy X-ray absorptiometry (DEXA) was performed in 50 HIV-infected children in a tertiary hospital in Madrid after a median length of HAART of 54 months. Subsequently, the group with bone mineral loss was compared with the group without bone mineral loss. RESULTS Forty percent of the children studied had decreased bone mineral density, of which 36 % had osteopenia (18/50) and 4 % had osteoporosis (2/50). No statistically significant differences were found between the two groups in any of the factors analyzed. CONCLUSIONS The prevalence of decreased bone mineral density in our cohort of HIV-infected children receiving HAART is high. The etiology and factors associated with this alteration are still not well known.

UI MeSH Term Description Entries
D008297 Male Males
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015519 Bone Density The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
March 2016, Indian journal of pediatrics,
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy.
April 2003, AIDS (London, England),
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
September 2003, AIDS (London, England),
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
November 2007, Pediatrics,
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
September 2001, AIDS (London, England),
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy.
August 2006, Clinical endocrinology,
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Predictors of mortality among HIV-infected children receiving highly active antiretroviral therapy.
February 2017, Medecine et maladies infectieuses,
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Anemia in HIV-infected patients receiving highly active antiretroviral therapy.
January 2002, Journal of acquired immune deficiency syndromes (1999),
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
January 2003, HIV clinical trials,
P Rojo Conejo, and J T Ramos Amador, and L García Piñar, and C Ruano Fajardo, and J M Sánchez Granados, and Ma I González Tomé, and J Ruiz Contreras
Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
May 2012, Clinical endocrinology,
Copied contents to your clipboard!